

# Serum but not mucosal antibody responses are predicted by pre-existing SARS-CoV-2 spike cross-reactive CD4<sup>+</sup> T cells following BNT162b2 vaccination in the elderly

Lil Meyer-Arndt<sup>1,2,3,4,5\*</sup>, Tatjana Schwarz<sup>6\*</sup>, Lucie Loyal<sup>1,2</sup>, Larissa Henze<sup>1,2</sup>,  
Beate Kruse<sup>1,2</sup>, Manuela Dingeldey<sup>1,2</sup>, Kübrah Gürcan<sup>7</sup>, Zehra Uyar-Aydin<sup>7</sup>,  
Marcel A. Müller<sup>6</sup>, Christian Drosten<sup>6</sup>, Friedemann Paul<sup>2,5</sup>, Leif E. Sander<sup>8</sup>, Ilja Demuth<sup>9,10</sup>,  
Roland Lauster<sup>7</sup>, Claudia Giesecke-Thiel<sup>11</sup>, Julian Braun<sup>1,2,\*</sup>, Victor M. Corman<sup>6,\*</sup>, §,  
Andreas Thiel<sup>1,2,\*</sup>, §

<sup>1</sup> Si-M / "Der Simulierte Mensch" a science framework of Technische Universität Berlin and Charité - Universitätsmedizin Berlin, Berlin, Germany

<sup>2</sup> Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Regenerative Immunology and Aging, BIH Center for Regenerative Therapies, 13353 Berlin, Germany

<sup>3</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, NeuroCure Clinical Research Center, 10117 Berlin, Germany

<sup>4</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neurology, 10117 Berlin, Germany

<sup>5</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, and Max Delbrueck Center for Molecular Medicine, Experimental and Clinical Research Center, Lindenberger Weg 80, 12135 Berlin, Germany

<sup>6</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Virology, 10117 Berlin, Germany

<sup>7</sup> Medical Biotechnology, Institute for Biotechnology, Technische Universität Berlin, Berlin, Germany

<sup>8</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Infectious Diseases and Respiratory Medicine, 13353 Berlin, Germany

<sup>9</sup> Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Endocrinology and Metabolic Diseases (including Division of Lipid Metabolism), Biology of Aging working group, Augustenburger Platz 1, 13353 Berlin, Germany

<sup>10</sup> Berlin Institute of Health at Charité – Universitätsmedizin Berlin, BCRT - Berlin Institute of Health Center for Regenerative Therapies, Berlin, Germany

<sup>11</sup> Max Planck Institute for Molecular Genetics, Ihnestraße 63-73, 14195 Berlin, Germany

\* equal contribution

§Co-Corresponding authors:

Andreas Thiel, BIH Center of Regenerative Therapies, Charité - Universitätsmedizin Berlin, Föhrer Straße 15, 13353 Berlin, Germany.

Email address: andreas.thiel@charite.de.

Victor M. Corman, Institute of Virology, Charité - Universitätsmedizin Berlin, 10117 Berlin, Germany.

Email address: victor.corman@charite.de.

**Keywords:** COVID-19 Vaccination; Immune System Aging; Antigen-specific T Cells; Antibody Response; Mucosal Immunity

52 **Abstract**

53 Advanced age is a main risk factor for severe COVID-19 and thus elderly were often prioritized  
54 for vaccination. However, low vaccination efficacy and accelerated waning immunity have  
55 been reported in this age group. To elucidate age-related differences in immunogenicity, we  
56 analysed cellular, serological and salivary SARS-CoV-2 spike glycoprotein-specific immune  
57 responses to BNT162b2 COVID-19 vaccine in old (69-92 years) and middle-aged (24-57  
58 years) vaccinees compared to natural infection (COVID-19 convalescents of 21-55 years).  
59 Serological humoral responses to vaccination exceeded those of convalescents but salivary  
60 anti-spike subunit 1 (S1) IgA and neutralizing capacity were less durable in vaccinees. In old  
61 vaccinees, we observed that pre-existing spike-specific CD4<sup>+</sup> T cells correlated with efficient  
62 induction of serological anti-S1 IgG and neutralizing capacity after vaccination. Our results  
63 highlight the role of pre-existing cross-reactive CD4<sup>+</sup> T cells with respect to SARS-CoV-2  
64 vaccination particularly in old individuals, in whom their presence predicted efficient COVID-  
65 19-vaccine-induced humoral immune responses.

66 **Main**

67 Global efforts have been mounted to develop efficient vaccines against coronavirus disease  
68 2019 (COVID-19) caused by the pandemic severe acute respiratory syndrome coronavirus 2  
69 (SARS-CoV-2)<sup>1</sup>. As severe COVID-19 mainly affects older individuals, many vaccination  
70 campaigns have prioritized the elderly population<sup>2</sup>. However, vaccination efficacy is known to  
71 be decreased in this age group as compared to younger individuals, particularly for primary  
72 vaccination<sup>3,4,5</sup>. For COVID-19 vaccination - given the distinct homology of certain antigen  
73 target regions of SARS-CoV-2 to common cold coronaviruses (HCoV) - one possible  
74 explanation could be an age-related reduced number of pre-existing cross-reactive CD4<sup>+</sup> T  
75 cells in old individuals<sup>6,7</sup>. To assess the immunogenicity of the COVID-19 vaccine in this  
76 particularly vulnerable age group and identify possible relations to pre-existing SARS-CoV-2-  
77 specific cross-reactivities, we examined systemic cellular, serological and salivary humoral  
78 SARS-CoV-2-specific immunity before and during the course of COVID-19 vaccination with  
79 BNT162b2 mRNA vaccine (Tozinameran™, Comirnaty™<sup>8,9</sup>) in old and comorbid nursing home  
80 residents (n=18; mean age 83±6) and their middle-aged caregivers (n=14; mean age 47±10)  
81 at baseline (prior to first vaccination), at day 28 (d28, 7 days after booster vaccination) and at  
82 day 49 (d49, 28 days after booster vaccination). For comparison with naturally acquired  
83 immunity, we additionally analysed COVID-19 convalescents (age-matched to the middle-  
84 aged cohort; mean age 36±11) after mild natural SARS-CoV-2 infection at ~d28 (n=10), ~d49  
85 (n=16) or ~d94 (n=11) after symptom onset (Table 1).

86

87 We first analysed anti-SARS-CoV-2 spike glycoprotein subunit 1 (S1) immunoglobulin G (IgG)  
88 and anti-S1 immunoglobulin A (IgA) antibody levels in serum (Fig. 1a and b). At d28, eight old  
89 donors (44%) failed to seroconvert for anti-S1 IgA and five of them (28%) also for anti-S1 IgG.  
90 In contrast, all middle-aged donors exhibited high anti-S1 IgG and anti-S1 IgA levels at d28  
91 indicating a fast and robust systemic humoral response to vaccination. Anti-S1 IgG and anti-  
92 S1 IgA levels were more heterogeneous and significantly lower in the old compared to the  
93 middle-aged cohort at d28 (Fig. 1a and b). At d49, anti-S1 IgG levels were still significantly

94 lower in the old vaccinees (Fig. 1a), but no significant differences were present in anti-S1 IgA at  
95 d49 comparing old and middle-aged vaccinees (Fig. 1b). Assessing S1-specific functional  
96 neutralization capacity in serum using a surrogate viral neutralization assay (sVNT), all middle-  
97 aged vaccinees demonstrated a prompt and uniform increase of virus neutralization at  
98 d28, which remained stable at d49 (Fig. 1c). In the old vaccinees, this response was  
99 significantly delayed and remained lower than in middle-aged vaccinees at d49 with one non-  
100 responder (inhibition < 30%). Compared to COVID-19 convalescents, anti-S1 IgG levels and  
101 median S1 neutralizing capacity in serum were more homogeneously distributed and, moreover,  
102 significantly higher in age-matched middle-aged and in old vaccinees at both time points (Fig.  
103 1a and c).

104  
105 To evaluate salivary humoral responses as potential correlate of first-line adaptive protection  
106 against SARS-CoV-2 infection, we furthermore analysed the presence of anti-S1 secretory IgA  
107 (slgA) in the saliva. Following vaccination, we observed increased levels of anti-S1 slgA  
108 in both the middle-aged and old cohort (Fig. 1d). At d28, anti-S1 slgA levels were significantly  
109 higher in the middle-aged donors as compared to the old individuals. All 14 middle-aged  
110 donors showed anti-S1 slgA levels above their age group's maximum pre-vaccination level  
111 (0.45 optical density (OD) ratio) while only six of the old vaccinees (60%) reached above their  
112 age group's maximum pre-vaccination level (0.31 OD ratio). At d49, we observed anti-S1  
113 slgA levels comparable to pre-vaccination in all vaccinees (Fig. 1d). By contrast, COVID-19  
114 convalescents exhibited significantly higher anti-S1 slgA levels at ~d49 and even ~d94  
115 compared to age-matched middle-aged vaccinees at d49 (Fig. 1d). S1 neutralizing activity in  
116 saliva developed more heterogeneously after vaccination (Fig. 1e). An increase in S1  
117 neutralizing activity was detected in most vaccinees at d28 but dropped back to pre-vaccination  
118 levels at d49 mirroring anti-S1 slgA kinetics (Fig. 1d and e). In some responsive old donors, a  
119 delayed anti-S1 slgA response was reflected by a similarly delayed increase of salivary S1  
120 neutralizing activity, which caused some old donors to show increased anti-S1 slgA and S1  
121 neutralizing activity at d49 (Fig. 1d und e). COVID-19 convalescents demonstrated higher S1

122 neutralizing capacity in the saliva around ~d49 compared to age-matched vaccinees at d49.  
123 In contrast to anti-S1 sIgA, S1 salivary neutralizing capacity did not remain significantly  
124 increased in convalescents at ~d94 compared to d49 in age-matched middle-aged vaccinees  
125 indicating that anti-S1 sIgA does not correspond to S1 neutralizing activity following infection  
126 at this time point (Fig. 1d und e).

127

128 Finally, we analysed frequencies of antigen-reactive CD40L<sup>+</sup> 4-1BB<sup>+</sup> CD4<sup>+</sup> T cells after *in vitro*  
129 stimulation with the N-terminal part (S1, covered by peptide mix S-I) and the C-terminal part  
130 (S2, peptide mix S-II) of the spike glycoprotein (Fig. 2a and b, Suppl. Fig. 2). We have recently  
131 demonstrated that, in contrast to the N-terminal part, the C-terminal part of the spike  
132 glycoprotein contains highly conserved domains and triggers CD4<sup>+</sup> T cell cross-reactivity to  
133 SARS-CoV-2<sup>10</sup>. One week after the second vaccination (d28), all middle-aged and 89% (S-I;  
134 n=16/18) and 94% (S-II; n=17/18) respectively of the old donors acquired T cell reactivity to S-  
135 I and S-II. However, S-I- and S-II-reactive T cell frequencies increased more quickly  
136 and peaked at a higher level in the middle-aged than in the old cohort. At d49, S-I- and S-II-  
137 reactive CD4<sup>+</sup> T cell frequencies of the middle-aged vaccinees dropped slightly so that both  
138 age groups reached comparable levels. In convalescents, we observed a significantly lower T  
139 cell reactivity to S-I and S-II at ~d49 after symptom onset compared to both vaccinated cohorts  
140 (Fig. 2a and b). Pre-existing T cell reactivity to S-II at baseline was significantly lower in old  
141 individuals than in the middle-aged cohort (Fig. 2b and c). Remarkably though, in these old  
142 individuals, high levels of S-II-specific, but not S-I-specific, CD4<sup>+</sup> T cells at baseline correlated  
143 with higher anti-S1 IgG and consistently with elevated S1 neutralizing capacity in serum at d28  
144 (Fig. 2d and e, Suppl. Fig. 1). These correlations did not exist for anti-S1 sIgA or salivary S1  
145 neutralizing capacity (Fig. 2f and g). Hence, in old vaccinees, increased pre-existing  
146 frequencies of S-II-specific CD4<sup>+</sup> T cells predicted the efficiency of neutralizing and anti-S1  
147 IgG humoral vaccination responses.

148

149 In this study, we investigated systemic and mucosal immune responses to the COVID-19  
150 mRNA vaccine BNT162b2 in middle-aged and old vaccinees compared to COVID-19  
151 convalescents (age-matched to middle-aged vaccinees). While the middle-aged cohort  
152 demonstrated a remarkably homogeneous and prompt induction of both cellular and humoral  
153 immune responses, a significantly decreased anti-S1 IgG response was observed in the old  
154 vaccinees after two doses of BNT162b2, which was intra-individually associated with an  
155 equally reduced anti-S1 IgA response (Suppl. Fig. 3). However, compared to COVID-19  
156 convalescents with a mild disease course, COVID-19 vaccination induced more pronounced  
157 systemic immunity with significantly higher levels of spike-reactive CD4<sup>+</sup> T cells, S1-specific  
158 antibodies and serum S1 neutralizing capacity regardless of age.

159 Reduced humoral and cellular vaccination responses in old individuals have been described  
160 for vaccines against influenza, yellow fever, pneumococcal disease, and tetanus as well as for  
161 COVID-19<sup>12-15</sup>. In the light of the increased risk of the elderly for severe COVID-19 and the  
162 current discussions on their need of booster vaccinations, it is essential to identify and evaluate  
163 possible predictors of low vaccination efficiency particularly in this age group. Several studies  
164 have supported the notion of beneficial effects of pre-exposure SARS-CoV-2 cross-reactivity<sup>6</sup>,  
165 <sup>16, 17</sup>. In the elderly, the frequency of these pre-existing S-II-specific CD4<sup>+</sup> T cells was reduced  
166 (Fig. 2b and c). However, whether this phenomenon has a direct effect on BNT162b2  
167 immunogenicity in the elderly was unclear. Our findings here highlight the relevance of pre-  
168 existing CD4<sup>+</sup> T cell cross-reactivity for an efficient immune response to COVID-19 vaccination  
169 particularly in this age group. Possible explanations for this age-related reduction of cross-  
170 reactivity could be cellular senescence or impaired (oronasal) mucosal immunity<sup>11, 18-20</sup>.

171 We additionally investigated anti-S1 sIgA in the saliva as a potential correlate of local mucosal  
172 protection from SARS-CoV-2 infection following COVID-19 vaccination as compared to natural  
173 infection. We assume that the presence of S1-specific antibodies and S1 neutralizing capacity  
174 in the saliva may contribute to protection against SARS-CoV-2 infection and reduce local  
175 replication<sup>21, 22</sup>. However, within four weeks (d49) after booster vaccination, anti-S1 sIgA levels  
176 and S1 neutralizing activity in the saliva returned to low levels. By contrast, COVID-19

177 convalescents exhibited significantly higher salivary anti-S1 sIgA levels and higher salivary S1  
178 neutralizing activity at ~d49 after symptom onset compared to age-matched vaccinees. We  
179 found a correlation between anti-S1 sIgA levels and salivary S1 neutralization in convalescents  
180 at ~d28 and at ~d49, which was not observed in vaccinees (Suppl. Fig. 4). This indicates that  
181 neutralizing capacity in the saliva following vaccination may not only rely on anti-S1 sIgA but  
182 possibly anti-S1 IgG, which is consistent with reports on detectable anti-S1 IgG in the saliva of  
183 vaccinated individuals<sup>23, 24</sup>. In COVID-19 convalescents, anti-S1 sIgA secretion in salivary  
184 glands (and salivary S1 neutralizing activity) is likely induced by locally primed B and T cells in  
185 nasopharyngeal lymph nodes and/or tonsils<sup>25</sup>. In contrast, the more transient presence of anti-  
186 S1 sIgA in the saliva of vaccinated individuals could be the result of transfusion of serum-  
187 derived anti-S1 IgA through the endothelium into the oral mucosa<sup>26</sup>. An alternative explanation  
188 would be mucosal homing of peripheral anti-S1 IgA plasmablasts although intra-muscular  
189 injection does not reliably induce mucosal homing<sup>27</sup>.

190

191 Taken together, the presence of anti-S1 sIgA and S1 neutralizing capacity in the saliva after  
192 vaccination is of shorter duration and lower magnitude than after natural infection, which points  
193 out the need to determine the role of mucosal immunity, e.g., in the form of sIgA in saliva, for  
194 evaluation of SARS-CoV-2 immunity and its transmission. Currently, vaccines for intranasal  
195 application are in development, which may fill the gap in mucosal immunity observed here<sup>28</sup>.

196 Our findings demonstrate that BNT162b2 induces strong immune responses in middle-aged  
197 as well as most old and comorbid individuals. However, for some old individuals, the  
198 serological response to vaccination is hampered and may leave these individuals at higher risk  
199 of infection and severe disease courses, thus promoting recommendations for regular immune  
200 status check-ups and further vaccination boosts. Importantly, we show here that pre-existing  
201 SARS-CoV-2 spike glycoprotein cross-reactive memory T cells predict vaccination efficiency  
202 in the elderly and may generally contribute to the high responsiveness to COVID-19 vaccines.



## 203 **Methods**

204

### 205 **Participants and ethics**

206 The study was approved by the ethics committee of Charité – Universitätsmedizin Berlin  
207 (EA/152/20) and was conducted in accordance with the Declaration of Helsinki. A written  
208 informed consent was obtained from all participants. The 39 participants (22 nursing home  
209 residents (old vaccinees), 17 caregivers (middle-aged vaccinees)) analysed for this study were  
210 recruited at three different nursing homes in Berlin between September and November 2020  
211 and were available for follow-up visits 28 days and 49 days after their first COVID-19  
212 vaccination in January and February 2021. Furthermore, we collected saliva and blood  
213 samples of a total of 36 COVID-19 convalescents with mild disease course (WHO II) at ~28  
214 (n=10), ~49 (n=16) or ~94 days (n=11) post symptom onset. Baseline data of vaccinees and  
215 data of convalescents had been collected and partially analysed as part of the Charité Corona  
216 Cross (CCC) study for a project investigating T cell cross-reactivity to SARS-CoV-2<sup>6</sup>. Visits  
217 included nasopharyngeal swabs, blood and saliva sampling at all time points. 4 older and 3  
218 middle-aged donors with signs of previous SARS-CoV-2 infection (either positive anti-S1 IgG  
219 levels or a S-I T cell stimulation index > 3.0 at baseline) were excluded from analysis.

220

### 221 **SARS-CoV-2 RT-qPCR**

222 Nasopharyngeal swabs for RT-qPCR were taken from all participants at all three time  
223 points. Vaccinees who tested positive by RT-PCR in the study period (n=2) were excluded  
224 from all analyses. Swab material was suspended in 4.3 ml Cobas PCR Media. RNA was  
225 extracted using the MagNA Pure 96 system (Roche). The viral RNA extraction was performed  
226 using 200 µl swab dilution eluted in 100 µl of extraction buffer. SARS-CoV-2 detection was  
227 based on two genomic targets (E- and N gene, TIB Molbiol) using 5 µl of the RNA eluate.  
228 Quantification of SARS-CoV-2 copy numbers was achieved using calibration curves with serial  
229 diluted photometrically quantified in-vitro transcribed RNA as described before<sup>20,21</sup>. RT-PCR  
230 was performed using the LightCycler 480 II (Roche).



231 **Blood sampling, serum preparation and PBMC isolation**

232 Whole blood was collected in lithium heparin tubes for peripheral blood mononuclear cell  
233 (PBMC) isolation and SST™II advance (all Vacutainer®, BD) tubes for serology. SST™II  
234 advance tubes were centrifuged at 1000 x g, 10 min and serum supernatant aliquots frozen at  
235 -80 °C until further use. PBMCs were isolated by gradient density centrifugation according to  
236 the manufacturer's instructions (Leucosep tubes, Greiner; Biocoll, Bio&SELL).

237

238 **Ex vivo T cell stimulation**

239 Freshly isolated PBMC were cultivated at  $5 \times 10^6$  PBMC in AB-medium containing RPMI 1640  
240 medium (Gibco) supplemented with 10% heat inactivated AB serum (Pan Biotech), 100 U/ml  
241 penicillin (Biochrom), 0.1 mg/ml streptomycin (Biochrom). Stimulations were conducted with  
242 11aa overlapping 15-mer PepMix™ SARS-CoV-2 spike glycoprotein peptide pool 1 or 2  
243 (termed here S-I and S-II; JPT) at concentrations of 1 µg/ml per peptide respectively.  
244 Stimulation controls were performed with equal concentrations of DMSO in PBS (unstimulated  
245 control) and 1 µg/ml per peptide of CEFX Ultra SuperStim pool (positive control; JPT). All  
246 approaches contained 1 µg/ml purified anti-CD28 (clone CD28.2, BD Biosciences). Incubation  
247 was performed at 37 °C, 5% CO<sub>2</sub> for 16 h in the presence of 10 µg/ml brefeldin A (Sigma-  
248 Aldrich) during the last 14 h.

249

250 **Flow Cytometry**

251 Stimulations were stopped by incubation in 20 mM EDTA for 5 min. Surface staining was  
252 performed for 15 min in the presence of 1 mg/ml beriglobin (CSL Behring) with the following  
253 fluorochrome-conjugated antibodies titrated to their optimal concentrations: CD3-FITC  
254 (REA613, Miltenyi), CD4-VioGreen (REA623, Miltenyi), CD8-VioBlue (REA734, Miltenyi),  
255 CD38-APC (REA671, Miltenyi), HLA-DR-PerCpVio700 (REA805, Miltenyi). During the last 10  
256 min of incubation, Zombie Yellow fixable viability staining (Biolegend) was added. Fixation and  
257 permeabilization were performed with eBioscience™ FoxP3 fixation and PermBuffer  
258 (Invitrogen) according to the manufacturer's protocol. Intracellular staining was carried out for

259 30 min in the dark at room temperature with 4-1BB-PE (REA765, Miltenyi) and CD40L-PE-  
260 Vio770 (REA238, Miltenyi). All samples were measured on a MACSQuant<sup>®</sup> Analyzer 16  
261 (Miltenyi) according to the gating strategy illustrated in Suppl. Fig. 2. Instrument performance  
262 was monitored prior to every measurement with Rainbow Calibration Particles (BD).

263

#### 264 **Anti-SARS-CoV-2 S1 enzyme-linked immunosorbent assay (ELISA) in serum and saliva**

265 Humoral responses to vaccination were determined by anti-SARS-CoV-2 S1 IgG and  
266 IgA testing. Anti-SARS-CoV-2 IgG and IgA tests in sera were performed using a commercially  
267 available ELISA kit (Euroimmun) as previously described<sup>22</sup>. Test results for sera were  
268 considered positive above an optical density (OD) ratio of 1.1. The same ELISA kit was used  
269 for anti-SARS-CoV-2 IgA tests in saliva. The assay was performed with 1:100 diluted serum  
270 and 1:10 diluted saliva samples. Values were capped at an OD ratio of 10. No positivity  
271 thresholds have yet been validated for saliva.

272

#### 273 **Surrogate virus neutralization assay (sVNT)**

274 A competition ELISA-based surrogate virus neutralization assay (sVNT; medac) mimicking the  
275 SARS-CoV-2 receptor (ACE2) binding process was used to identify neutralizing anti-SARS-  
276 CoV-2 antibodies in participant serum and saliva<sup>23,24</sup>. The assay was performed with 1:10  
277 diluted serum and 1:5 diluted saliva samples respectively following the manufacturer's  
278 instructions. Inhibition activity above 30 % was considered positive in serum.

279

#### 280 **Data processing and statistical analysis**

281 Study data were collected and managed using REDCap electronic data capture tools hosted  
282 at Charité<sup>25,26</sup>. Flow cytometry data were analysed using FlowJo 10 (BD). Prism 9  
283 (GraphPad) was used for data plotting. For statistical group comparisons between  
284 antibody OD ratios and T cell frequencies, non-parametric testing (Mann-Whitney U-test) and  
285 ROUT outlier tests were performed. Statistical significance was reported as follows: \* $p \leq 0.05$ ,  
286 \*\* $p \leq 0.01$ , \*\*\* $p \leq 0.001$ . Correlation coefficients were reported as  $r$ . CD4<sup>+</sup> T cell activation was

287 plotted as stimulation index (StimIndex), i.e., ratio of % of CD40L<sup>+</sup>4-1BB<sup>+</sup> CD4<sup>+</sup> T cells in  
288 stimulated samples and % of CD40L<sup>+</sup>4-1BB<sup>+</sup> CD4<sup>+</sup> T cells in unstimulated controls (zero  
289 background values were set to a minimum of 0.001 before division). Lines in figures displaying  
290 T cell stimulation results indicate stimulation indices of 1.5 (above background; dashed line)  
291 and 3.0 (positivity threshold; dotted line)<sup>6</sup>.

## 292 **Acknowledgment and Funding**

293 We thank the CCC Study Group E. Baysal, T. Panne, F. Legler, M. Girod, B. Bohnen, T.  
294 Nguyen, J. Schmitz, R. Klemencic, L. Hintze, N. Avinc, P. Resch, A. Maraj, A. Farghaly, P.  
295 Schulz, K. Du, N. Matuschewski, K. Gutwenger, I. Katsianas, Z. Cheng, A. Braginetz for their  
296 contributions to donor recruitment, sample processing and measurement. Furthermore, we  
297 thank T. Bleicker, J. Tesch, P. Tscheak, M. L. Schmidt, P. Mackeldanz and J. Riege for their  
298 support in conducting ELISA and PCR analyses. We also thank Andreas Hetey for support  
299 with maintaining the REDCap database and Nicola Brindle for critical reading of the  
300 manuscript. This work was funded by the German Federal Ministry of Health to A.T. (Charité  
301 Corona Cross (CCC) and Charité Corona Cross 2.0 (CCC 2.0)) and to C.D. and V.M.C  
302 (Konsiliarlabor für Coronaviren) by the German Ministry of Research through  
303 VARIPath (01KI2021) to V.M.C, by the German Research Foundation through KFO339 to J.B.  
304 and in part by the German Federal Ministry of Education and Research  
305 (Bundesministerium für Bildung und Forschung, BMBF) to NaFoUniMedCovid19 – COVIM,  
306 FKZ: 01KX2021.

307

## 308 **Author Contributions**

309 Conceptualization: LMA, JB, VMC, AT. Data Analysis: LMA, TS, JB. Funding acquisition: CD,  
310 VMC, AT. Resources: LMA, TS, LL, LH, BK, MD, KG, ZUA, MAM, LES, ID, RL, JB. Writing:  
311 LMA, CGT, JB, VMC, AT.

312

## 313 **Competing Interests**

314 VMC and MAM are named together with Euroimmun on a patent application filed recently  
315 regarding detection of antibodies against SARS-CoV-2.

316

## 317 **Data and materials availability**

318 The datasets generated during the current study are available from the corresponding author  
319 on reasonable request.

## 320 References

- 321 1. Krammer, F. SARS-CoV-2 vaccines in development. *Nature* **586(7830)**, 516-527 (2020).
- 322 2. Zheng, Z. et al. Risk factors of critical & mortal COVID-19 cases: A systemic literature review  
323 and meta-analysis. *J Infect* **81(2)**, e16-e25 (2020).
- 324 3. Osterholm, M. T., Kelley, N. S., Sommer, A. & Belongia E. A. Efficacy and effectiveness of  
325 influenza vaccines: a systematic review and meta-analysis. *Lancet Infect Dis* **12(1)**, 33-44  
326 (2012).
- 327 4. Siegrist, A.-C. & Aspinall, R. B-cell responses to vaccination at the extremes of age. *Nat Rev*  
328 *Immunol* **9(3)**, 185-94 (2009).
- 329 5. Schwarz, T. et al. Delayed Antibody and T-Cell Responses to BNT162b2 Vaccination in the  
330 Elderly, Germany. *Emerg Infect Dis* **27(8)** (2021).
- 331 6. Loyal, L. et al. Cross-reactive CD4<sup>+</sup> T cells enhance SARS-CoV-2 immune responses upon  
332 infection and vaccination. *Science* **373**, 6558 (2021).
- 333 7. Saletti, G. et al. Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human  
334 coronaviruses OC43 and NL63. *Sci Rep* **10(1)**, 21447 (2020).
- 335 8. Polack, F.P et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med*  
336 **383(27)**, 2603-2615 (2020).
- 337 9. Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2  
338 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination  
339 campaign in Israel: an observational study using national surveillance data. *Lancet* **397(10287)**,  
340 1819-1829 (2021).
- 341 10. Braun J. et al. SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.  
342 *Nature* **587(7833)**, 270-274 (2020).
- 343 11. Aiello, A. et al. Immunosenescence and its hallmarks: How to oppose aging strategically? A  
344 review of potential options für therapeutic intervention. *Front Immunol* **10**, 2247 (2019).
- 345 12. Assaad., U., El-Masri., I., Porhomayon J., El-Solh., A.A.. Pneumonia immunization in older  
346 adults: review of vaccine effectiveness and strategies. *Clin Interv Aging* **7**:543-61(2012).
- 347 13. Schatz., D. et al. Aging and the Immune Response to Tetanus Toxoid: Diminished Frequency  
348 and Level of Cellular Immune Reactivity to Antigenic Stimulation. *Clin Diagn Lab Immunol*  
349 **5(6)**:894-6 (1998).


- 350 14. Schulz, A.R. et al. Low Thymic Activity and Dendritic Cell Numbers Are Associated with the  
351 Immune Response to Primary Viral Infection in Elderly Humans. *J Immunol* **195(10)**:4699-711  
352 (2015).
- 353 15. Jürchott, K. et al. Highly Predictive Model for a Protective Immune Response to the  
354 A(H1N1)pdm2009 Influenza Strain after Seasonal Vaccination. *PLoS One* **8**;11(3) (2016).
- 355 16. Mateus, J. et al. Low-dose mRNA-1273 COVID-19 vaccine generates durable memory  
356 enhanced by cross-reactive T cells. *Science* **eabj9853** (2021).
- 357 17. Niessl, J. et al. Identification of resident memory CD8<sup>+</sup> T cells with functional specificity for  
358 SARS-CoV-2 in unexposed oropharyngeal lymphoid tissue. *Sci Immunol* **eabk0894** (2021).
- 359 18. Heaney, J. L. J. et al. Salivary Functional Antibody Secretion Is Reduced in Older Adults: A  
360 Potential Mechanism of Increased Susceptibility to Bacterial Infection in the Elderly. *J Gerontol*  
361 *A Biol Sci Med Sci* **70(12)**:1578-85 (2015).
- 362 19. Sato, S. et al. Mucosal Immunosenescence In The Gastrointestinal Tract.  
363 *Gerontology* **61(4)**:336-42 (2015).
- 364 20. Miletic, I. D. et al. Salivary IgA secretion rate in young and elderly persons. *Physiol Behav*  
365 **60(1)**:243-8 (1996).
- 366 21. Renegar, K.B., Small Jr., P.A., Boykins, L.G. & Wright, P.F. Role of IgA versus IgG in the control  
367 of influenza viral infection in the murine respiratory tract. *J Immunol* **173(3)**, 1978-86 (2004).
- 368 22. Mantis, N.J. & Forbes, S.J. Secretory IgA: Arresting microbial pathogens at epithelial borders.  
369 *Immunol Invest* **39(0)**, 383-406 (2010).
- 370 23. Sterlin, D. et al. IgA dominates the early neutralizing antibody response to SARS-CoV-2.  
371 *Sci Transl Med* **13(577)**, 2223 (2021).
- 372 24. Ketas, T. J. et al. Antibody Responses to SARS-CoV-2 mRNA Vaccines Are Detectable in  
373 Saliva. *Pathog Immun* **6(1)**, 116-134 (2021).
- 374 25. Zuercher, A. W., Coffin, S. E., Thurnheer, M. C., Fundova, P. & Cebra, J. J. Nasal-associated  
375 lymphoid tissue is a mucosal inductive site for virus-specific humoral and cellular immune  
376 responses. *J Immunol* **168(4)**, 1796-803 (2002).
- 377 26. Langereis, J. D., Jacobs, J. F. M., de Jonge, M. I. & van Deuren, M. Plasma therapy leads to  
378 an increase in functional IgA and IgM concentration in the blood and saliva of a patient with X-  
379 linked agammaglobulinemia. *J Transl Med* **17(1)**, 174 (2019).

- 380 27. Seong, Y. et al. Trafficking receptor signatures define blood plasmablasts responding to tissue-  
381 specific immune challenge. *JCI Insight* **2(6)**:e90233.
- 382 28. Lund, F.E. & Randall, T.D. Scent of a vaccine.
- 383 29. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.  
384 *Euro Surveill* **25(3)**, 2000045 (2020).
- 385 30. Wölfel, R. et al. Virological assessment of hospitalized patients with COVID-2019. *Nature*  
386 **581(7809)**, 465-469 (2020).
- 387 31. Von Rhein, C. et al. Comparison of potency assays to assess SARS-CoV-2 neutralizing  
388 antibody capacity in COVID-19 convalescent plasma. *J Virol Methods* **288**:114031 (2021).
- 389 32. Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-  
390 mediated blockage of ACE2-spike protein-protein interaction. *Nat Biotechnol*  
391 **38(9)**:1073-1078.
- 392 33. Okba, N. M. A. et al. Severe Acute Respiratory Syndrome Coronavirus 2 – Specific Antibody  
393 Responses in Coronavirus Disease Patients. *Emerg Infect Dis* **26(7)**, 1478-1488 (2020).
- 394 34. Harris, P. A. et al. The REDCap consortium: Building an international community of software  
395 platform partners. *J Biomed Inform* **95**, 103208 (2019).
- 396 35. Harris, P. A. et al. Research electronic data capture (REDCap)—A metadata-driven  
397 methodology and workflow process for providing translational research informatics support. *J*  
398 *Biomed Inform* **42(2)**, 377-81 (2009).
- 399



400 **Figures and Figure Legends**

**Figure 1**




401  
 402 **Fig. 1: Serological and salivary antibody responses. a, b and d, anti-S1 serum IgG (a) and**  
 403 **IgA (b) and anti-S1 saliva sIgA (d) OD ratios in the old and middle-aged vaccinees at BL, d28**  
 404 **and d49 after BNT162b2 vaccination and in COVID-19 convalescents at ~d28, ~d49 or ~d94**  
 405 **(only for saliva) after symptom onset. c and e, quantification of SARS-CoV-2**  
 406 **receptor (ACE2) binding inhibition in serum (c) and in saliva (e) in percent in the old and**  
 407 **middle-aged vaccinees at BL, d28 and d49 after BNT162b2 vaccination and in COVID-19**  
 408 **convalescents at ~d28, ~d49 or ~d94 (only for saliva) after symptom onset. Salivary anti-S1**  
 409 **sIgA and ACE2 binding inhibition are displayed as means of up to three saliva samples on**  
 410 **consecutive days. Antibody results are demonstrated in OD ratios. Positivity thresholds for**  
 411 **serology: antibody OD ratio > 1.1 (dotted lines in a and b); neutralizing capacity > 30% (dotted**  
 412 **lines in c). Red dots represent old vaccinees, white middle-aged vaccinees, blue**  
 413 **convalescents. Grey lines connect follow-up samples. ns = non-significant,  $p \leq 0.05 = *$ ,  $p$**   
 414  **$\leq 0.01 = **$ ,  $p \leq 0.001 = ***$ ,  $p \leq 0.0001 = ****$  according to the Mann-Whitney U-test.**

415

416

**Figure 2**



417

418 **Fig. 2: Age- and exposure-dependant CD4<sup>+</sup> T cell reactivity to S-I and S-II. a and b,**

419 stimulation indices (StimIndex) of S-I- and S-II peptide pool-specific CD40L<sup>+</sup> 4-

420 1BB<sup>+</sup> CD4<sup>+</sup> T cells in the old and middle-aged vaccinees at baseline (BL), d28 and d49 after

421 BNT162b2 vaccination and in COVID-19 convalescents at ~d28 or ~d49 after symptom onset.

422 **c,** StimIndex of S-I- and S-II-specific CD40L<sup>+</sup> 4-1BB<sup>+</sup> CD4<sup>+</sup> T cells in the very old and middle-

423 aged vaccinees at BL grouped according to stimulation for direct comparison. **d and f,** anti-S1

424 serum IgG (**d**) and anti-S1 saliva sIgA (**f**) OD ratios in the old and middle-aged vaccinees at

425 d28 grouped according to S-II-specific CD4<sup>+</sup> T cell reactivity at BL (StimIndex > 1.5). **e and g,**

426 inhibition in serum (**e**) and in saliva (**g**) in the old and middle-aged vaccinees at d28 grouped

427 according to S-II-specific CD4<sup>+</sup> T cell reactivity at BL (StimIndex > 1.5). Positivity thresholds:

428 CD4<sup>+</sup> T cells StimIndex (dashed lines) > 1.5 (positive, above background) and (dotted lines) >

429 3.0 (certainly positive). Red dots represent old vaccinees, white middle-aged vaccinees, blue

430 convalescents. Grey lines connect follow-up samples. ns = non-significant, p ≤ 0.05 = \*, p

431 ≤ 0.01 = \*\*, p ≤ 0.001 = \*\*\*, p ≤ 0.0001 = \*\*\*\* according to the Mann-Whitney U-test.


432

433

434 **Supplementary Figures and Figure Legends**

435

**Supplementary Figure 1**



436

437


438 **Suppl. Fig. 1: Correlation of pre-existing T cell reactivity to S-I with anti-S1 IgG response.**

439 Anti-S1 serum IgG OD ratios in serum in the old (red dots) and middle-aged (white dots)

440 vaccinees at d28 grouped according to S-I-specific CD4<sup>+</sup> T cell reactivity at BL (StimIndex >

441 1.5).

**Supplementary Figure 2**



442

443 **Suppl. Fig. 2: Gating scheme.** The gating scheme is displayed for one representative donor's

444 CEFX-stimulation utilized as positive control. Doublets were removed from lymphocytic


445 populations via FSC-H vs -W and SSC-H vs -W and dead cells via Zombie Yellow live/dead

446 stain. Subsequently, CD4<sup>+</sup> cells were gated within CD3<sup>+</sup> T cells. Antigen-reactive CD4<sup>+</sup> T cells

447 were identified via CD40L and 4-1BB staining.

448

### Supplementary Figure 3




449

450 **Suppl. Fig. 3: Correlation of anti-S1 IgG and anti-S1 IgA in serum after vaccination.** Anti-  
451 S1 IgG OD ratios in serum correlated with anti-S1 IgA in serum at d28 and d49, respectively,  
452 in the old (red dots) and middle-aged (white dots) vaccinees.  $r$  = correlation coefficient,  $p \leq 0.05$   
453 = significant according to Spearman's rank.

454

### Supplementary Figure 4



455

456

457 **Suppl. Fig. 4: Correlation of virus inhibition with anti-S1 sIgA in saliva after vaccination**  
458 **or infection.** S1 virus inhibition in saliva at d28 and d49 correlated with salivary anti-S1 sIgA  
459 OD ratios at d28 and d49 respectively in the old (red dots) and middle-aged (white dots)  
460 vaccinees and in convalescents (blue dots).  $r$  = correlation coefficient,  $p \leq 0.05$  = significant  
461 according to Spearman's rank.

462 **Tables**

463 **Table 1.** Donor characteristics. SD = standard deviation.

<b>Cohort</b>	<b>Number (#)</b>	<b>Sex (female)</b>	<b>Mean age in years [SD]</b>	<b>Mean # of days between symptom onset and BL [SD]</b>
Vaccinated elderly	18	11	82.56 [5.82]	
Vaccinated middle-aged	14	13	47.36 [10.10]	
COVID-19 convalescents (unvaccinated) ~d28 after symptom onset	10	6	33.8 [10.32]	27.2 [5.01]
COVID-19 convalescents (unvaccinated) ~d49 after symptom onset	16	12	34.94 [11.53]	49.19 [6.45]
COVID-19 convalescents (unvaccinated) ~d94 after symptom onset	11	6	39.40 [10.67]	93.90 [9.02]

464